Aptevo reports 10 newly diagnosed AML patients advanced to stem cell transplant after Mipletamig combo treatment

Aptevo reported that 10 patients with newly diagnosed acute myeloid leukaemia (AML) advanced to allogeneic stem cell transplant after receiving Mipletamig in combination with Venetoclax and Azacitidine, representing 21% of the frontline AML patient population in the study.

Detected & updated continuously · Source: Nebula